Optimizing treatment with thioguanine derivatives in inflammatory bowel disease.
Thioguanine derivatives, azathioprine and 6-mercaptopurine, represent major drugs in the treatment of chronic active inflammatory bowel disease. They are effective in two-thirds of the patients and safe over the long term in patients who can tolerate them (80-90%). Recent progress in understanding the metabolism of these drugs and its implication in clinical practice have brought up new tools and strategies that are proposed to optimize treatment. In particular, the measurement and characterization of key enzymes and metabolites may have clinical impact. Thus, thiopurine methyl transferase genotyping and activity measurement, as well as erythrocytes, 6-thioguanine nucleotides and 6-methyl mercaptopurine levels, may help in some situations of intolerance or inefficacy with these drugs. Indications for starting and stopping treatment with thioguanine derivatives are also discussed.
Louis
Edouard
E
Service de Gastroentérologie, CHU de Liège, 4000 Liège, Belgium.
Belaiche
Jacques
J
D001379:Azathioprine / Q000378:metabolism / Q000627:therapeutic use*; D002908:Chronic Disease; D006801:Humans; D007166:Immunosuppressive Agents / Q000378:metabolism / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D015122:Mercaptopurine / Q000378:metabolism / Q000627:therapeutic use*; D013866:Thioguanine / Q000031:analogs & derivatives / Q000378:metabolism* / Q000627:therapeutic use*
D007166:Immunosuppressive Agents; D015122:Mercaptopurine; D013866:Thioguanine; D001379:Azathioprine